Long-term clinical outcome of differentiated thyroid cancer patients with undetectable stimulated thyroglobulin level one year after initial treatment

Thyroid

Volumn 22, Issue 8, 2012, Pages 784-790

  Han, Ji Min ^a   Kim, Won Bae ^a   Yim, Ji Hye ^a   Kim, Won Gu ^a   Kim, Tae Yong ^a   Ryu, Jin Sook ^a   Gong, Gyungyub ^a   Sung, Tae Yon ^a   Yoon, Jong Ho ^a   Hong, Suck Joon ^a   Kim, Eui Young ^b   Shong, Young Kee ^a  

^a University of Ulsan College of Medicine   (South Korea)

^b Dongnam Institute of Radiological and Medical Science   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

THYROGLOBULIN;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER RECURRENCE; CERVICAL LYMPH NODE; CLINICAL EVALUATION; COHORT ANALYSIS; DIFFERENTIATED THYROID CANCER; FEMALE; FOLLOW UP; HOSPITAL; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PATIENT REFERRAL; PREDICTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; THYROGLOBULIN BLOOD LEVEL;

ADOLESCENT; ADULT; AGED; CELL DIFFERENTIATION; COHORT STUDIES; FEMALE; HUMANS; IODINE RADIOISOTOPES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RETROSPECTIVE STUDIES; THYROGLOBULIN; THYROID NEOPLASMS; THYROIDECTOMY; THYROTROPIN; TREATMENT OUTCOME;

EID: 84864700771     PISSN: 10507256     EISSN: 15579077     Source Type: Journal    
DOI: 10.1089/thy.2011.0322     Document Type: Article

References (26)

1. Cailleux AF, Baudin E, Travagli JP, Ricard M, Schlumberger M 2000 Is diagnostic iodine-131 scanning useful after total thyroid ablation for differentiated thyroid cancer? J Clin Endocrinol Metab 85:175-178.
2. Schlumberger M, Baudin E 1998 Serum thyroglobulin determination in the follow-up of patients with differentiated thyroid carcinoma. Eur J Endocrinol 138:249-252.
3. Pacini F, Capezzone M, Elisei R, Ceccarelli C, Taddei D, Pinchera A 2002 Diagnostic 131-iodine whole-body scan may be avoided in thyroid cancer patients who have undetectable stimulated serum Tg levels after initial treatment. J Clin Endocrinol Metab 87:1499-1501.
4. Tuttle RM, Tala H, Shah J, Leboeuf R, Ghossein R, Gonen M, Brokhin M, Omry G, Fagin JA, Shaha A 2010 Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system. Thyroid 20:1341-1349.
5. Mazzaferri EL, Kloos RT 2001 Clinical review 128: Current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab 86:1447-1463.
6. Cooper DS, Doherty GM, Haugen BR, Hauger BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Pacini F, Schlumberger M, Sherman SI, Steward DL, Tuttle RM 2009 Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19:1167-1214.
7. Pacini F,Molinaro E,CastagnaMG,Agate L, Elisei R, Ceccarelli C, Lippi F, Taddei D, Grasso L, Pinchera A 2003 Recombinant human thyrotropin-stimulated serumthyroglobulin combined with neck ultrasonography has the highest sensitivity in monitoring differentiated thyroid carcinoma. J Clin Endocrinol Metab 88:3668-3673.
8. Torlontano M, Attard M, Crocetti U, Tumino S, Bruno R, Costante G, D'Azzo G, Meringolo D, Ferretti E, Sacco R, Arturi F, Filetti S 2004 Follow-up of low risk patients with papillary thyroid cancer: Role of neck ultrasonography in detecting lymph node metastases. J Clin Endocrinol Metab 89:3402-3407.
9. Nascimento C, Borget I, Al Ghuzlan A, Deandreis D, Chami L, Travagli JP, Hartl D, Lumbroso J, Chougnet C, Lacroix L, Baudin E, Schlumberger M, Leboulleux S 2011 Persistent disease and recurrence in differentiated thyroid cancer patients with undetectable postoperative stimulated thyroglobulin level. Endocr Relat Cancer 18:R29-R40.
10. Castagna MG, Brilli L, Pilli T, Montanaro A, Cipri C, Fioravanti C, Sestini F, Capezzone M, Pacini F 2008 Limited value of repeat recombinant human thyrotropin (rhTSH)-stimulated thyroglobulin testing in differentiated thyroid carcinoma patients with previous negative rhTSH-stimulated thyroglobulin and undetectable basal serum thyroglobulin levels. J Clin Endocrinol Metab 93:76-81.
11. Crocetti U, Durante C, Attard M, Maniglia A, Tumino S, Bruno R, Bonfitto N, Dicembrino F, Varraso A, Meringolo D, Filetti S, Trischitta V, Torlontano M 2008 Predictive value of recombinant human TSH stimulation and neck ultrasonography in differentiated thyroid cancer patients. Thyroid 18:1049-1053.
12. Kloos RT, Mazzaferri EL 2005A single recombinant human thyrotropin-stimulated serum thyroglobulin measurement predicts differentiated thyroid carcinoma metastases three to five years later. J Clin Endocrinol Metab 90:5047-5057.
13. Klubo-Gwiezdzinska J, Burman KD, van Nostrand D, Wartofsky L 2011 Does an undetectable rhTSH-stimulated Tg level 12 months after initial treatment of thyroid cancer indicate remission? Clin Endocrinol (Oxf) 74:111-117.
14. Mazzaferri EL, Kloos RT 2002 Is diagnostic iodine-131 scanning with recombinant human TSH useful in the followup of differentiated thyroid cancer after thyroid ablation? J Clin Endocrinol Metab 87:1490-1498.
15. Baudin E, Do Cao C, Cailleux AF, Leboulleux S, Travagli JP, Schlumberger M 2003 Positive predictive value of serum thyroglobulin levels, measured during the first year of follow-up after thyroid hormone withdrawal, in thyroid cancer patients. J Clin Endocrinol Metab 88:1107-1111.
16. Bachelot A, Cailleux AF, Klain M, Baudin E, Ricard M, Bellon N, Caillou B, Travagli JP, Schlumberger M 2002 Relationship between tumor burden and serum thyroglobulin level in patients with papillary and follicular thyroid carcinoma. Thyroid 12:707-711.
17. Bachelot A, Leboulleux S, Baudin E, Hartl DM, Caillou B, Travagli JP, Schlumberger M 2005 Neck recurrence from thyroid carcinoma: Serum thyroglobulin and high-dose total body scan are not reliable criteria for cure after radioiodine treatment. Clin Endocrinol (Oxf) 62:376-379.
18. Kloos RT 2010 Thyroid cancer recurrence in patients clinically free of disease with undetectable or very low serum thyroglobulin values. J Clin Endocrinol Metab 95:5241-5248.
19. Torlontano M, Crocetti U, D'Aloiso L, Bonfitto N, Di Giorgio A, Modoni S, Valle G, Frusciante V, Bisceglia M, Filetti S, Schlumberger M, Trischitta V 2003 Serum thyroglobulin and 131I whole body scan after recombinant human TSH stimulation in the follow-up of low-risk patients with differentiated thyroid cancer. Eur J Endocrinol 148:19-24.
20. Spencer CA, LoPresti JS, Fatemi S, Nicoloff JT 1999 Detection of residual and recurrent differentiated thyroid carcinoma by serum thyroglobulin measurement. Thyroid 9:435-441.
21. Spencer C, Petrovic I, Fatemi S 2011 Current thyroglobulin autoantibody (TgAb) assays often fail to detect interfering TgAb that can result in the reporting of falsely low/undetectable serum Tg IMA values for patients with differentiated thyroid cancer. J Clin Endocrinol Metab 96:1283-1291.
22. Tubiana M, Schlumberger M, Rougier P, Laplanche A, Benhamou E, Gardet P, Caillou B, Travagli JP, Parmentier C 1985 Long-term results and prognostic factors in patients with differentiated thyroid carcinoma. Cancer 55:794-804.
23. Tennvall J, Biorklund A, Moller T, Ranstam J, Akerman M 1986 Is the EORTC prognostic index of thyroid cancer valid in differentiated thyroid carcinoma? Retrospective multivariate analysis of differentiated thyroid carcinoma with long follow-up. Cancer 57:1405-1414.
24. Kim TY, Kim WB, Kim ES, Ryu JS, Yeo JS, Kim SC, Hong SJ, Shong YK 2005 Serum thyroglobulin levels at the time of 131I remnant ablation just after thyroidectomy are useful for early prediction of clinical recurrence in low-risk patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab 90:1440-1445.
25. KimWG, Yoon JH, KimWB,KimTY,KimEY,KimJM, Ryu JS, Gong G, Hong SJ, Shong YK 2008 Change of serum antithyroglobulin antibody levels is useful for prediction of clinical recurrence in thyroglobulin-negative patients with differentiated thyroid carcinoma. J Clin EndocrinolMetab 93:4683-4689.
26. CastagnaMG, Tala JuryHP, Cipri C, Belardini V, Fioravanti C, Pasqui L, Sestini F, Theodoropoulou A, Pacini F 2011 The use of ultrasensitive thyroglobulin assays reduces but does not abolish the need for TSH stimulation in patients with differentiated thyroid carcinoma. J Endocrinol Invest 34:e219-e223.